Wandercraft's acquisition of Ekso Bionics means existing users stay supported under one larger company. Clinic and home device owners keep their current hardware and care path. An exoskeleton is a wearable robot that powers standing and walking. On Oct.
1, 2026, Wandercraft announced it acquired Ekso Bionics, Inc. from a ChronoScale Holdings subsidiary, according to Wandercraft in its acquisition announcement. The deal was signed and closed at the same time, with both boards approving and terms undisclosed. Wandercraft stated it intends to keep supporting Eve, Indego Personal, Atalante X and EksoNR.
Table of Contents
- Will clinic care change?
- What does it mean for home users?
- How do you get Eve?
- Will Medicare cover a personal device?
Will clinic care change?
For rehabilitation centers, the near-term effect is scale rather than disruption. Wandercraft reported in its combined company announcement that Atalante X and EksoNR together support standing and walking at more than 700 centers. Those systems hold FDA clearances and CE marks for stroke, spinal cord injury, multiple sclerosis and acquired brain injury.
For therapists and patients, that means familiar devices, protocols and staff training remain in place. A larger combined fleet can also simplify parts, service and multi-site programs. Ask your clinic which system it uses and whether scheduling or support contacts change.
What does it mean for home users?
For personal mobility, the acquisition joins two home-oriented products under one owner. Eve is the first FDA-cleared self-balancing personal exoskeleton, according to Wandercraft in its Eve launch announcement. It is cleared for eligible adult wheelchair users with spinal cord injury at any neurological level who can operate its controller.
Eve enables hands-free upright movement without crutches. Wandercraft said it will continue supporting Eve, Indego Personal and the individuals who rely on them. Current owners should keep using prescribed maintenance and contact their existing provider until told otherwise.
How do you get Eve?
Wandercraft commercially launched Eve in the U.S. on Sept. 17, 2026.
Access runs through exclusive distributor National Seating & Mobility and its more than 180 locations. The process is clinical, fitted and supervised. Start with a referral to an Eve evaluation site. Bring your injury history, wheelchair details and a companion who can train with you.
- clinical evaluation and trial to check eligibility
- physician order and paperwork
- custom fitting and manufacture
- companion-inclusive training for home use
Will Medicare cover a personal device?
Medicare created an important billing precedent before the acquisition. Ekso Bionics reported in its Medicare payment announcement that CMS set a final payment level of $91,031.93 for Ekso Indego Personal under code K1007, effective April 1, 2024. In August 2024, Ekso Bionics said Medicare contractors completed claims processing and paid a first lump-sum reimbursement for Indego Personal.
That history matters for Eve because it established the billing path. Coverage still requires documented eligibility and medical necessity under K1007, according to Base Reality Group. Candidates can stop at evaluation, trial, physician order, paperwork or training, so a code does not guarantee home use. Confirm eligibility, documentation and out-of-pocket costs in writing before ordering.
